Lebrikizumab
- Generic Name
- Lebrikizumab
- Brand Names
- Ebglyss
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 953400-68-5
- Unique Ingredient Identifier
- U9JLP7V031
- Background
Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1188
- Registration Number
- NCT04392154
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Modern Research Associates, Dallas, Texas, United States
🇺🇸Paddington Testing Company Inc, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 309
- Registration Number
- NCT02546700
- Locations
- 🇺🇸
Centex Studies, Houston, Texas, United States
🇺🇸Comprehensive Clinical Research Inc., Berlin, New Jersey, United States
🇺🇸Clinical Research Inst. of Southern Oregon, Pc, Medford, Oregon, United States
A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02546869
A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT02486809
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT02465606
- Locations
- 🇺🇸
Allergy and Asthma Relief Experts, Granada Hills, California, United States
🇺🇸T. Joseph Raoof Md, Inc., Encino, California, United States
🇺🇸Allergy and Asthma Associates of Southern California - CRN, Mission Viejo, California, United States
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 212
- Registration Number
- NCT02340234
- Locations
- 🇨🇦
The Centre for Dermatology, Richmond Hill, Ontario, Canada
🇩🇪Universitätsklinik Bonn, Bonn, Germany
🇫🇮Helsinki University Central Hospital; Skin & Allergy Hospital, Helsinki, Finland
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
- Conditions
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 313
- Registration Number
- NCT02104674
A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma
- Conditions
- Interventions
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT02099656
- Locations
- 🇺🇸
University of Miami School of Medicine - Sylvester at Deerfield, Deerfield Beach, Florida, United States
🇺🇸Pen Memory Center, Philadelphia, Pennsylvania, United States
🇬🇧St Mary's Hospital, London, United Kingdom
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 230
- Registration Number
- NCT01987492
- Locations
- 🇧🇪
Clin Univ de Bxl Hôpital Erasme, Bruxelles, Belgium
🇦🇺Monash Medical Centre; Respiratory and Sleep Medicine, Clayton, Victoria, Australia
🇧🇪Longartsenpraktijk, Genk, Belgium
A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 348
- Registration Number
- NCT01875003
- Locations
- 🇺🇸
Allergy & Asthma Consultants, Redwood City, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸The Clinical Research Center, Shiloh, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.